In light of these findings, we aimed to explored the relationship between mTOR/eIF4E activation and immunotherapy response in an EBV‐positive GC cohort, which contains 16 patients received induction chemotherapy combined with anti‐PD‐1 immunotherapy before surgical resection. The gene discussed is MTOR; the disease is gastric cancer.